Branded Legacy Subsidiary Acquires Vancouver Facility to Advance Addiction Treatment Technologies

Branded Legacy, Inc. (OTC: BLEG), a biotechnology company focused on addiction treatment and harm reduction, announced that its subsidiary, BioLegacy Evaluative Group, has acquired a 22,000-square-foot commercial property in Vancouver, Canada. The strategic acquisition positions the company at the epicenter of one of North America's most severe drug crises, enabling direct collaboration with affected communities while advancing critical harm reduction technologies.

The new facility, designed to meet Good Manufacturing Practice (GMP) standards and equipped with ISO Class 7 and 8 clean rooms, will serve as a comprehensive laboratory and manufacturing hub. This infrastructure is essential for developing safe, effective devices and products designed to counteract hazardous substances and reduce associated harms. The location's significance cannot be overstated, as Vancouver has been grappling with an unprecedented opioid crisis that has claimed thousands of lives and overwhelmed healthcare systems.

The acquisition represents a substantial commitment to addressing the addiction epidemic through scientific innovation and community engagement. BioLegacy's work will be supported by research partnerships with leading academic institutions, including McMaster University and Stanford University's Dr. Eran Bendavid. These collaborations are expected to accelerate the development of evidence-based solutions that can be rapidly deployed in crisis situations.

Branded Legacy's patented intranasal naloxone delivery device, which enhances accessibility and dosing precision for opioid overdose treatment, will benefit from the expanded manufacturing capabilities. The technology platform also enables nasal delivery of vaccines and other medications, creating opportunities for rapid pandemic response and improved access to medical treatments in underserved regions globally. For more information about the company's initiatives, visit https://BrandedLegacy.com.

The Vancouver facility acquisition signals a growing recognition that the addiction crisis requires sophisticated scientific approaches combined with community-centered implementation. By establishing operations directly within affected communities, BioLegacy aims to develop solutions that are not only technologically advanced but also culturally appropriate and accessible to those most in need. This approach represents a significant shift in how biotechnology companies engage with public health crises, moving beyond traditional laboratory settings to embrace ground-level problem-solving.

The investment in GMP-compliant manufacturing infrastructure underscores the company's commitment to producing medical-grade products that meet rigorous safety standards. This is particularly important for harm reduction technologies, where product reliability can mean the difference between life and death. The facility's clean room capabilities will enable the production of sterile medical devices and pharmaceutical products, ensuring that innovations reaching the market meet the highest quality standards required for medical applications.